(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2014 (25.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/151683 A8

(51) **International Patent Classification**:
C07K 16/00 (2006.01) ***C12P 21/08*** (2006.01)

(21) **International Application Number**:
PCT/US2014/026237

(22) **International Filing Date**:
13 March 2014 (13.03.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/787,753 15 March 2013 (15.03.2013) US
61/791,537 15 March 2013 (15.03.2013) US

(71) **Applicant**: **BAYER HEALTHCARE LLC** [US/US]; 100 Bayer Boulevard, P.O. Box 915, Whippany, New Jersey 07981-0915 (US).

(72) **Inventors**: **BAUZON, Maxine**; 1033 Park Street, Hercules, California 94547 (US). **HERMISTON, Terry**; 305 E. Strawberry Drive, Mill Valley, California 94941 (US).

(74) **Agent**: **HIGHLANDER, Steven, L.**; Parker Highlander, PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX78746 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version**:
1 October 2015

(15) **Information about Correction**:
see Notice of 1 October 2015

WO 2014/151683 A8

(54) **Title**: GLA DOMAINS AS THERAPEUTIC AGENTS

(57) **Abstract**: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.